CRISPR-Cas9 Single Nucleotide Editing of Tuberous Sclerosis Complex 2 Gene in Mesenchymal Stem Cells

Area of Science:

• Genetics
• Molecular Biology
• Cancer Research

Background:

• Tuberous sclerosis complex 2 (TSC2) gene regulates the mTOR pathway, crucial for cell growth.
• Loss-of-function TSC2 mutations drive tumor development and are linked to poor prognosis in cancers like breast cancer.
• Point mutations are the most common TSC2 mutations found in databases.

Purpose of the Study:

• To assess the feasibility of inducing specific TSC2 point mutations in mesenchymal stem cells (MSCs).
• To evaluate CRISPR-Cas9 delivery methods for targeted TSC2 mutation induction.
• To establish a method for studying TSC2 mutation effects in primary cells.

Main Methods:

• Utilized CRISPR-Cas9 gene editing technology.
• Targeted three frequent TSC2 point mutations: c.1864 C>T (p.Arg622Trp), c.1832 G>A (p.Arg611Glu), and c.5024 C>T (p.Pro1675Leu).
• Employed lipofectamine-based transfection and another delivery method for CRISPR-Cas9 in human MSCs (hMSCs).

Main Results:

• Achieved high editing efficiency, up to 85%, for inducing TSC2 point mutations in hMSCs.
• Lipofectamine-based transfection proved effective for delivering CRISPR-Cas9 components.
• Demonstrated successful induction of specific TSC2 mutations in primary hMSCs.

Conclusions:

• High editing efficiency for TSC2 mutations is achievable in primary hMSCs using CRISPR-Cas9.
• This technique enables the induction and potential reversal of mutations without cell line derivation.
• Facilitates research into TSC2-related cancers and the mTOR pathway in primary cell models.